ArticleJournal of medicinal chemistry2018
Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.
Article in Journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 97 citations in OpenAlex.
- Manganese-Templated Nontrivial Structures for MRI and Therapy.Journal of the American Chemical Society · 2026Article
- Quality Assurance Strategies for Brain State Characterization by MEMRI.bioRxiv : the preprint server for biology · 2026Article
- Superhydrophilic FeAngewandte Chemie (International ed. in English) · 2025Article
- First-in-Human Safety, Tolerability, Efficacy, and Pharmacokinetics of Pegfosimer Manganese (SN132D) for Contrast-Enhanced MRI of Breast Cancer.Investigative radiology · 2025Article
- Design of Mn(1,4-DO2A) derivatives as stable and inert contrast agents for magnetic resonance imaging.Communications chemistry · 2025Article
- Facile construction of manganese-based contrast agent with highRegenerative biomaterials · 2025Article
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- Synthesizing Contrast-Enhanced MR Images from Noncontrast MR Images Using Deep Learning.AJNR. American journal of neuroradiology · 2024Article
- Endeavor toward Redox-Responsive Transition Metal Contrast Agents Based on the Cross-Bridge Cyclam Platform.Inorganic chemistry · 2024Article
- Quantum Mimicry With Inorganic Chemistry.Comments on modern chemistry. Part A, Comments on inorganic chemistry : a journal of critical discussion of the current literature · 2024Article
- Mn-Based MRI Contrast Agents: An Overview.Molecules (Basel, Switzerland) · 2023Review
- Liposomal MRI probes containing encapsulated or amphiphilic Fe(III) coordination complexes.Biomaterials science · 2023Article
- Development of a Suite of Gadolinium-Free OATP1-Targeted Paramagnetic Probes for Liver MRI.Journal of medicinal chemistry · 2023Article
- Manganese (II) Complex of 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid (NOTA) as a Hepatobiliary MRI Contrast Agent.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Rationally Designed Complex Replenishes the Transferrin Iron Pool Directly and with High Specificity.Journal of the American Chemical Society · 2023Article
- Mn-Based Methacrylated Gellan Gum Hydrogels for MRI-Guided Cell Delivery and Imaging.Bioengineering (Basel, Switzerland) · 2023Article
- A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging.Nature biomedical engineering · 2023Article
- Principles and applications of magnetic nanomaterials in magnetically guided bioimaging.Materials today physics · 2023Article
- Novel Salinomycin-Based Paramagnetic Complexes-First Evaluation of Their Potential Theranostic Properties.Pharmaceutics · 2022Article
- Thermodynamic Stability of Mn(II) Complexes with Aminocarboxylate Ligands Analyzed Using Structural Descriptors.Inorganic chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe. Of particular concern are the acyclic chelates that remain available for liver scans, where there is an unmet diagnostic need and no replacement technology. To address this concern, we evaluated our previously reported Mn-based MRI contrast agent, Mn-PyC3A, and nine newly synthesized derivatives as liver specific MRI contrast agents. Within this focused library the transient liver uptake and rate of blood clearance are directly correlated with log P. The complex Mn-PyC3A-3-OBn emerged as the lead candidate due to a combination of high relaxivity, rapid blood clearance, and avid hepatocellular uptake. Mn-PyC3A-3-OBn rendered liver tumors conspicuously hypo-intense in a murine model and is wholly eliminated within 24 h of injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.